Impact of SARS-CoV-2 spike stability and RBD exposure on antigenicity and immunogenicity

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

Extent: 1 Online-Ressource.

Language: Englisch

Bibliographic citation: Impact of SARS-CoV-2 spike stability and RBD exposure on antigenicity and immunogenicity ; volume:14 ; number:1 ; day:8 ; month:3 ; year:2024 ; pages:1-10 ; date:12.2024
Scientific reports ; 14, Heft 1 (8.3.2024), 1-10, 12.2024

Creator: Rutten, Lucy
Swart, Maarten
Koornneef, Annemart
Bouchier, Pascale
Blokland, Sven
Sadi, Ava
Juraszek, Jarek
Vijayan, Aneesh
Schmit-Tillemans, Sonja
Verspuij, Johan
Choi, Ying
Daal, Chenandly E.
Perkasa, Aditya
Torres Morales, Shessy
Myeni, Sebenzile K.
Kikkert, Marjolein
Tolboom, Jeroen
Manen, Daniëlle van
Kuipers, Harmjan
Schuitemaker, Hanneke
Zahn, Roland
Langedijk, Johannes P. M.

Contributor: SpringerLink (Online service)

DOI: 10.1038/s41598-024-56293-x

URN: urn:nbn:de:101:1-2405112114362.522603700040

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 14.08.2025, 10:54 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Rutten, Lucy
Swart, Maarten
Koornneef, Annemart
Bouchier, Pascale
Blokland, Sven
Sadi, Ava
Juraszek, Jarek
Vijayan, Aneesh
Schmit-Tillemans, Sonja
Verspuij, Johan
Choi, Ying
Daal, Chenandly E.
Perkasa, Aditya
Torres Morales, Shessy
Myeni, Sebenzile K.
Kikkert, Marjolein
Tolboom, Jeroen
Manen, Daniëlle van
Kuipers, Harmjan
Schuitemaker, Hanneke
Zahn, Roland
Langedijk, Johannes P. M.
SpringerLink (Online service)

Other Objects (12)

Immunogenicity of SARS-CoV-2 spike antigens derived from Beta & Delta variants of concern

Safety and immunogenicity of a recombinant protein RBD fusion heterodimer vaccine against SARS-CoV-2

Immunogenicity phase II study evaluating booster capacity of nonadjuvanted AKS-452 SARS-Cov-2 RBD Fc vaccine

Baculovirus displaying SARS-CoV-2 spike RBD promotes neutralizing antibody production in a mouse model

Development of multivalent nanobodies blocking SARS-CoV-2 infection by targeting RBD of spike protein

Potent neutralization of SARS-CoV-2 variants by RBD nanoparticle and prefusion-stabilized spike immunogens

Antibodies to the RBD of SARS-CoV-2 spike mediate productive infection of primary human macrophages

Recombinant ACE2 protein protects against acute lung injury induced by SARS-CoV-2 spike RBD protein

Stabilizing the closed SARS-CoV-2 spike trimer

MVA-based vaccine candidates encoding the native or prefusion-stabilized SARS-CoV-2 spike reveal differential immunogenicity in humans

Obesity does not influence SARS-CoV-2 humoral vaccine immunogenicity

A SARS‐CoV‐2 Spike Binding DNA Aptamer that Inhibits Pseudovirus Infection by an RBD‐Independent Mechanism **

Immunogenicity of SARS-CoV-2 spike antigens derived from Beta & Delta variants of concern

Safety and immunogenicity of a recombinant protein RBD fusion heterodimer vaccine against SARS-CoV-2

Immunogenicity phase II study evaluating booster capacity of nonadjuvanted AKS-452 SARS-Cov-2 RBD Fc vaccine

Baculovirus displaying SARS-CoV-2 spike RBD promotes neutralizing antibody production in a mouse model

Development of multivalent nanobodies blocking SARS-CoV-2 infection by targeting RBD of spike protein

Potent neutralization of SARS-CoV-2 variants by RBD nanoparticle and prefusion-stabilized spike immunogens

Antibodies to the RBD of SARS-CoV-2 spike mediate productive infection of primary human macrophages

Recombinant ACE2 protein protects against acute lung injury induced by SARS-CoV-2 spike RBD protein

Stabilizing the closed SARS-CoV-2 spike trimer

MVA-based vaccine candidates encoding the native or prefusion-stabilized SARS-CoV-2 spike reveal differential immunogenicity in humans

Obesity does not influence SARS-CoV-2 humoral vaccine immunogenicity

A SARS‐CoV‐2 Spike Binding DNA Aptamer that Inhibits Pseudovirus Infection by an RBD‐Independent Mechanism **

Immunogenicity of SARS-CoV-2 spike antigens derived from Beta & Delta variants of concern

Safety and immunogenicity of a recombinant protein RBD fusion heterodimer vaccine against SARS-CoV-2

Immunogenicity phase II study evaluating booster capacity of nonadjuvanted AKS-452 SARS-Cov-2 RBD Fc vaccine

Baculovirus displaying SARS-CoV-2 spike RBD promotes neutralizing antibody production in a mouse model

Development of multivalent nanobodies blocking SARS-CoV-2 infection by targeting RBD of spike protein

Potent neutralization of SARS-CoV-2 variants by RBD nanoparticle and prefusion-stabilized spike immunogens

Antibodies to the RBD of SARS-CoV-2 spike mediate productive infection of primary human macrophages

Recombinant ACE2 protein protects against acute lung injury induced by SARS-CoV-2 spike RBD protein

Stabilizing the closed SARS-CoV-2 spike trimer

MVA-based vaccine candidates encoding the native or prefusion-stabilized SARS-CoV-2 spike reveal differential immunogenicity in humans

Obesity does not influence SARS-CoV-2 humoral vaccine immunogenicity

A SARS‐CoV‐2 Spike Binding DNA Aptamer that Inhibits Pseudovirus Infection by an RBD‐Independent Mechanism **

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Impact of SARS-CoV-2 spike stability and RBD exposure on antigenicity and immunogenicity

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Immunogenicity of SARS-CoV-2 spike antigens derived from Beta & Delta variants of concern

Safety and immunogenicity of a recombinant protein RBD fusion heterodimer vaccine against SARS-CoV-2

Immunogenicity phase II study evaluating booster capacity of nonadjuvanted AKS-452 SARS-Cov-2 RBD Fc vaccine

Baculovirus displaying SARS-CoV-2 spike RBD promotes neutralizing antibody production in a mouse model

Development of multivalent nanobodies blocking SARS-CoV-2 infection by targeting RBD of spike protein

Potent neutralization of SARS-CoV-2 variants by RBD nanoparticle and prefusion-stabilized spike immunogens

Antibodies to the RBD of SARS-CoV-2 spike mediate productive infection of primary human macrophages

Recombinant ACE2 protein protects against acute lung injury induced by SARS-CoV-2 spike RBD protein

Stabilizing the closed SARS-CoV-2 spike trimer

MVA-based vaccine candidates encoding the native or prefusion-stabilized SARS-CoV-2 spike reveal differential immunogenicity in humans

Obesity does not influence SARS-CoV-2 humoral vaccine immunogenicity

A SARS‐CoV‐2 Spike Binding DNA Aptamer that Inhibits Pseudovirus Infection by an RBD‐Independent Mechanism **

Immunogenicity of SARS-CoV-2 spike antigens derived from Beta & Delta variants of concern

Safety and immunogenicity of a recombinant protein RBD fusion heterodimer vaccine against SARS-CoV-2

Immunogenicity phase II study evaluating booster capacity of nonadjuvanted AKS-452 SARS-Cov-2 RBD Fc vaccine

Baculovirus displaying SARS-CoV-2 spike RBD promotes neutralizing antibody production in a mouse model

Development of multivalent nanobodies blocking SARS-CoV-2 infection by targeting RBD of spike protein

Potent neutralization of SARS-CoV-2 variants by RBD nanoparticle and prefusion-stabilized spike immunogens

Antibodies to the RBD of SARS-CoV-2 spike mediate productive infection of primary human macrophages

Recombinant ACE2 protein protects against acute lung injury induced by SARS-CoV-2 spike RBD protein

Stabilizing the closed SARS-CoV-2 spike trimer

MVA-based vaccine candidates encoding the native or prefusion-stabilized SARS-CoV-2 spike reveal differential immunogenicity in humans

Obesity does not influence SARS-CoV-2 humoral vaccine immunogenicity

A SARS‐CoV‐2 Spike Binding DNA Aptamer that Inhibits Pseudovirus Infection by an RBD‐Independent Mechanism **

Immunogenicity of SARS-CoV-2 spike antigens derived from Beta & Delta variants of concern

Safety and immunogenicity of a recombinant protein RBD fusion heterodimer vaccine against SARS-CoV-2

Immunogenicity phase II study evaluating booster capacity of nonadjuvanted AKS-452 SARS-Cov-2 RBD Fc vaccine

Baculovirus displaying SARS-CoV-2 spike RBD promotes neutralizing antibody production in a mouse model

Development of multivalent nanobodies blocking SARS-CoV-2 infection by targeting RBD of spike protein

Potent neutralization of SARS-CoV-2 variants by RBD nanoparticle and prefusion-stabilized spike immunogens

Antibodies to the RBD of SARS-CoV-2 spike mediate productive infection of primary human macrophages

Recombinant ACE2 protein protects against acute lung injury induced by SARS-CoV-2 spike RBD protein

Stabilizing the closed SARS-CoV-2 spike trimer

MVA-based vaccine candidates encoding the native or prefusion-stabilized SARS-CoV-2 spike reveal differential immunogenicity in humans

Obesity does not influence SARS-CoV-2 humoral vaccine immunogenicity

A SARS‐CoV‐2 Spike Binding DNA Aptamer that Inhibits Pseudovirus Infection by an RBD‐Independent Mechanism **

Related objects

Reset password